MAP2K7 and metastatic melanoma: Prognostic subgroups defined by particular disease characteristics and gene expression signatures that affect survival outcomes have been identified in patients with BRAFV600-mutated metastatic melanoma treated with BRAF and MEK inhibitors.10–12 We additionally evaluated the association between depth of response and survival outcomes within these prognostic subgroups.